You have 9 free searches left this month | for more free features.

empagliflozin

Showing 1 - 25 of 130

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Glycogen Storage Disease Type IB Trial in Shanghai (Empagliflozin)

Recruiting
  • Glycogen Storage Disease Type IB
  • Empagliflozin
  • Shanghai, Shanghai, China
    Xinhua Hospital, Shanghai Jiao Tong University School of Medicin
Jul 17, 2023

Type 1 Diabetes Trial (Empagliflozin, Placebo)

Not yet recruiting
  • Type 1 Diabetes
  • Empagliflozin
  • Placebo
  • (no location specified)
Aug 31, 2023

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +2 more
  • Boston, Massachusetts
    Bringham Women Hospital
Jan 9, 2023

Emp-Activity: Empagliflozin Functional Capacity

Not yet recruiting
  • Heart Failure
  • Empagliflozin
  • (no location specified)
Aug 5, 2022

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,

Not yet recruiting
  • Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
  • (no location specified)
Jan 22, 2023

Kidney Transplant, Type 2 Diabetes Trial in United States (Empagliflozin)

Not yet recruiting
  • Kidney Transplant
  • Type 2 Diabetes
  • Empagliflozin
  • Iowa City, Iowa
  • +3 more
Aug 22, 2023

Ulcerative Colitis Trial (Empagliflozin, conventional treatment)

Not yet recruiting
  • Ulcerative Colitis
  • Empagliflozin
  • conventional treatment
  • (no location specified)
Nov 9, 2022

End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis Trial (Empagliflozin, Placebo)

Not yet recruiting
  • End-stage Kidney Disease
  • +7 more
  • Empagliflozin
  • Placebo
  • (no location specified)
Jan 9, 2023

T2DM Trial (Chiglitazar, Empagliflozin, Atorvastatin)

Not yet recruiting
  • T2DM
  • (no location specified)
Dec 27, 2022

Metabolic-associated Fatty Liver Disease, Type 2 Diabetes Trial (Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide)

Not yet recruiting
  • Metabolic-associated Fatty Liver Disease
  • Type 2 Diabetes
  • Empagliflozin
  • +2 more
  • (no location specified)
Oct 1, 2022

Diabetes, Type 2 Trial (Semaglutide, Empagliflozin)

Withdrawn
  • Diabetes Mellitus, Type 2
  • (no location specified)
Nov 11, 2022

Cystic Fibrosis-related Diabetes, Cystic Fibrosis Trial in Minneapolis (Empagliflozin, Placebo Control)

Not yet recruiting
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis
  • Empagliflozin
  • Placebo Control
  • Minneapolis, Minnesota
    University of Minnesota
Nov 20, 2023

PreDiabetes, Prediabetic State, Overweight and Obesity Trial in Corvallis (Empagliflozin, Multivitamin-Placebo)

Recruiting
  • PreDiabetes
  • +2 more
  • Empagliflozin
  • Multivitamin-Placebo
  • Corvallis, Oregon
    Oregon State University
Jul 19, 2022

Novel Antidiabetic Medications and Their Effect on Liver

Completed
  • Non-Alcoholic Fatty Liver Disease
  • Liver Steatosis
  • Empagliflozin
  • +2 more
  • Athens, Attiki, Greece
    "Hippocration" General Hospital of Athens
Jul 13, 2023

MDD Trial in New York (Empagliflozin)

Not yet recruiting
  • Major Depressive Disorder
  • Empagliflozin
  • New York, New York
    NYU Langone Health
Feb 24, 2023

Polycystic Kidney, Autosomal Dominant Trial in Aurora (Empagliflozin, Placebo)

Not yet recruiting
  • Polycystic Kidney, Autosomal Dominant
  • Empagliflozin
  • Placebo
  • Aurora, Colorado
    University of Coloardo Anschutz Medical Campus
Aug 18, 2022

Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD) Trial run by the National Institute of Allergy and

Recruiting
  • Crohn's Disease
  • +2 more
  • Empagliflozin
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Empagliflozin in Type 2 Diabetes Population With and Without

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +3 more
  • Durham, North Carolina
    Duke Clinical Research Institute
Aug 8, 2022

Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
Aug 19, 2022

Renal Insufficiency, Chronic Trial in Mansoura, Tanta (Metformin, Empagliflozin, Standard therapy)

Recruiting
  • Renal Insufficiency, Chronic
  • Mansoura, Dakahlia Governorate, Egypt
  • +1 more
May 12, 2022

Postprandial Hypoglycemia Trial in Basel (empagliflozin, anakinra, saline subcutaneous (s.c.) ())

Recruiting
  • Postprandial Hypoglycemia
  • empagliflozin
  • +3 more
  • Basel, Switzerland
    Department of Endocrinology, Diabetes and Metabolism, University
Apr 19, 2022

Type 2 Diabetes to Assess Risk of Liver Injury, Kidney Injury,

Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • DPP-4 inhibitors
  • One Or Multiple Sites, United Kingdom
    RTI health solutions
Aug 2, 2022

Healthcare Cost and Resource Utilization in Type 2 Diabetes and

Withdrawn
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • empagliflozin
  • +2 more
  • Ridgefield, Connecticut
    Boehringer Ingelheim Pharmaceuticals Inc
May 30, 2022

Type 2 Diabetes Trial in Seoul (Teneligliptin, Empagliflozin, Teneligliptin and Empagliflozin)

Completed
  • Type 2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Clinical Pharmacology, Asan Medical Center
Nov 8, 2021

Empa PASS on Urinary Tract Malignancies

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • +2 more
  • Helsinki, Finland
  • +2 more
Aug 8, 2022